KRYS Stock Analysis: Buy, Sell, or Hold?
KRYS - Krystal Biotech, Inc. Common Stock
$347.00
6.79 (2.00%)
▲
5d:
+7.31%
30d:
+15.88%
90d:
+40.43%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 03, 2026
Get Alerted When KRYS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: KRYS shows positive signals but monitor for confirmation. Market pricing in 6.1% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: KRYS shows positive signals but monitor for confirmation. Market pricing in 6.1% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$455.56
Based on 12.8% avg growth
INTRINSIC VALUE TODAY
$282.87
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: KRYS is currently trading at $347.00, which is considered extended relative to its 30-day fair value range of $296.44 to $330.73. From a valuation perspective, the stock is trading at a premium (Forward PE: 33.8) compared to its historical average (28.3). At these levels, the market is pricing in 6.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, KRYS is in a strong uptrend. The price is approaching resistance at $356.50. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: KRYS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, KRYS is in a strong uptrend. The price is approaching resistance at $356.50. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: KRYS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$296.44 -
$330.73
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
64.6%
Protect Your Profits
KRYS is technically overbought (RSI 71). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($339.22)
- NEUTRAL: Trading at premium valuation - market expects 6.1% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$296.44 -
$330.73
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$19.46
(5.6%)
Support & Resistance Levels
Support Level
$302.29
Resistance Level
$356.50
Current Trend
Strong Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
33.76
Wall Street Target
$339.22
(-0.3%)
Revenue Growth (YoY)
31.9%
Earnings Growth (YoY)
52.5%
Profit Margin
53.9%
Valuation Premium vs History
+6.1% premium
PE vs Historical
33.8 vs 28.3
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+6.1%
(market-implied from PE analysis)
1-Year Target
$360.96
(+6%)
2-Year Target
$382.98
(+13%)
3-Year Target
$406.34
(+19%)
3-Yr Target (if PE normalizes)
(PE: 34→28)
PE COMPRESSION
$340.59
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 33.8, Growth: 21.5%)
$610.70
(+80%)
Base:
(SPY PE: 21.8, Growth: 21.5%)
$393.95
(+16%)
Bear:
(PE: 18.5, Growth: 21.5%)
$334.86
(-2%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (46x PE), but valuation improves significantly next year (34x PE) as earnings recover.
Trailing PE: 46.21 | Current EPS (TTM): $7.46
Bull Case
$512.21
(+51%)
Analyst growth 35.1%, PE expands to 50.8
Base Case
$465.65
(+37%)
Market implied 35.1%, PE stable at 46.2
Bear Case
$234.42
(-31%)
Severe decline -20.0%, PE contracts to 39.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: June 24, 2026 12:50 PM ET
Data refreshes hourly during market hours. Next update: 1:50 PM
Data refreshes hourly during market hours. Next update: 1:50 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KRYS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Suma Krishnan
SELL
25000 shares
2026-03-04
Kathryn Romano
SELL
750 shares
2026-03-02
Daniel Janney
SELL
11803 shares
2026-02-27
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 65 BUY |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 54 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 67 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 59 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 52 HOLD |
Advanced KRYS Option Strategies
Professional options setups generated by AI based on today's KRYS price and gamma walls.
